Suppr超能文献

中国艾滋病防治重大挑战——2024年第五届研讨会,云南

Grand Challenges on HIV/AIDS in China - The 5th Symposium, Yunnan 2024.

作者信息

Chen Zhiwei, Xu Jianqing, Jin Xia, Wang Jianhua, Huang Jinghe, Zhang Hui, Chen Ling, Deng Kai, Cai Weiping, Li Linghua, Wang Fusheng, Wu Zhiwei, Shang Hong, Wu Hao

机构信息

AIDS Institute and Department of Microbiology, State Key Laboratory of Emerging Infectious Diseases, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, People's Republic of China.

Center for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, People's Republic of China.

出版信息

Emerg Microbes Infect. 2025 Dec;14(1):2492208. doi: 10.1080/22221751.2025.2492208. Epub 2025 Apr 22.

Abstract

HIV-1 infection has led to 1.329 million people living with the virus and 0.474 millions of deaths by the middle of 2024 in China. Achieving the goal of ending HIV/AIDS in China by 2030 has faced several grand challenges including currently having a diagnostic rate of less than 85%, an estimated annual cost burden of 6.3 billion RMB for antiretroviral therapy (ART) alone, and the lack of therapeutic cure and preventive vaccine and so on. To address these challenges, Chinese scientists initiated the programme of (GCC) in 2017. The inauguration symposium was held from 30 November to 1 December 2017 in Hong Kong - Asia's World City - to commemorate the 10th anniversary of AIDS Institute at The University of Hong Kong and Comprehensive AIDS Research Center at Tsinghua University. The mission of the GCC is to advance HIV/AIDS prevention, prioritize research on therapeutic cure and vaccine, disseminate new scientific findings, and foster broader collaborations. Following the inaugural event, subsequent symposia were held at Fudan University in 2018, Sun Yat-Sen University in 2019, Tsinghua University in 2023, and Dali University in 2024. This review reports the scientific presentations and progresses made by the GCC scientists, highlighting efforts to combat HIV/AIDS in China.

摘要

截至2024年年中,中国有132.9万人感染了HIV-1病毒,47.4万人死亡。到2030年在中国实现终结艾滋病的目标面临着诸多重大挑战,包括目前诊断率低于85%、仅抗逆转录病毒疗法(ART)的估计年度成本负担就达63亿元人民币,以及缺乏治疗性治愈方法和预防性疫苗等。为应对这些挑战,中国科学家于2017年启动了全球华人艾滋病研究与防治联盟(GCC)计划。成立座谈会于2017年11月30日至12月1日在香港——亚洲国际都会——举行,以纪念香港大学艾滋病研究所和清华大学艾滋病综合研究中心成立10周年。GCC的使命是推进艾滋病预防工作,优先开展治疗性治愈和疫苗研究,传播新的科学发现,并促进更广泛的合作。成立活动之后,后续座谈会分别于2018年在复旦大学、2019年在中山大学、2023年在清华大学以及2024年在大理大学举行。本综述报告了GCC科学家的学术报告和取得的进展,重点介绍了中国抗击艾滋病的努力。

相似文献

1
Grand Challenges on HIV/AIDS in China - The 5th Symposium, Yunnan 2024.
Emerg Microbes Infect. 2025 Dec;14(1):2492208. doi: 10.1080/22221751.2025.2492208. Epub 2025 Apr 22.
2
Thirty years of HIV and AIDS: future challenges and opportunities.
Ann Intern Med. 2011 Jun 7;154(11):766-71. doi: 10.7326/0003-4819-154-11-201106070-00345. Epub 2011 May 31.
3
Leveraging HIV treatment to end AIDS, stop new HIV infections, and avoid the cost of inaction.
Clin Infect Dis. 2014 Jul;59 Suppl 1(Suppl 1):S3-6. doi: 10.1093/cid/ciu321.
4
Leveraging early HIV diagnosis and treatment in Thailand to conduct HIV cure research.
AIDS Res Ther. 2019 Sep 6;16(1):25. doi: 10.1186/s12981-019-0240-4.
6
Thorny issues in the ethics of AIDS vaccine trials.
Lancet. 2003 Sep 20;362(9388):992. doi: 10.1016/S0140-6736(03)14371-1.
7
HIV/AIDS responses in China should focus on the impact of global integration.
Biosci Trends. 2018;12(5):507-509. doi: 10.5582/bst.2018.01269.
8
[The Médicins sans Frontières HIV/AIDS programme in Ukraine].
Ned Tijdschr Geneeskd. 2007 Dec 1;151(48):2685-9.
9
Scientific approaches to AIDS prevention and control in China.
Adv Dent Res. 2011 Apr;23(1):10-2. doi: 10.1177/0022034511398871.
10
Prevention and control of HIV/AIDS in China: lessons from the past three decades.
Chin Med J (Engl). 2021 Nov 10;134(23):2799-2809. doi: 10.1097/CM9.0000000000001842.

引用本文的文献

本文引用的文献

1
Estimates of HIV Incidence, Prevalence, and Mortality in China 2018.
J Med Virol. 2024 Dec;96(12):e70048. doi: 10.1002/jmv.70048.
2
Deubiquitinase USP37 enhances the anti-HIV-2/SIV ability of the host restriction factor SAMHD1.
J Virol. 2025 Jan 31;99(1):e0185824. doi: 10.1128/jvi.01858-24. Epub 2024 Dec 10.
3
The host restriction factor SERINC5 inhibits HIV-1 transcription by negatively regulating NF-κB signaling.
J Biol Chem. 2025 Jan;301(1):108058. doi: 10.1016/j.jbc.2024.108058. Epub 2024 Dec 7.
5
Functional variability of Nef in antagonizing SERINC5 during acute to chronic HIV-1 infection.
AIDS. 2025 Mar 1;39(3):229-240. doi: 10.1097/QAD.0000000000004079. Epub 2024 Dec 4.
6
Chinese guidelines for the diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2024 edition).
Chin Med J (Engl). 2024 Nov 20;137(22):2654-2680. doi: 10.1097/CM9.0000000000003383. Epub 2024 Nov 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验